Free Trial
NASDAQ:INTS

Intensity Therapeutics Q3 2025 Earnings Results & Report

Intensity Therapeutics logo
$3.06 -0.02 (-0.49%)
As of 03:40 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Intensity Therapeutics met analyst earnings expectations in its Q3 2025 results, released November 6, 2025. The company reported EPS of -$1.50 versus the -$1.50 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

Intensity Therapeutics EPS Results

Actual EPS
-$1.50
Consensus EPS
-$1.50
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 7 quarters

Intensity Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Intensity Therapeutics Q3 2025 Earnings FAQ

Intensity Therapeutics (NASDAQ:INTS) reported earnings of -$1.50 per share for Q3 2025, matching the consensus estimate of -$1.50. The report was announced on Thursday, November 6, 2025.

Intensity Therapeutics Earnings Headlines

What is HC Wainwright's Estimate for INTS FY2026 Earnings?
Brookline Capital Markets Forecasts INTS FY2026 Earnings
Buy Stocks… A Crash is Coming
Think stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges investors not to sell before hearing his 2027 prediction. He warns that by November 30th, Congress is set to make a move he believes will trigger a historic buying panic. Economists call the phenomenon a crack-up boom. Rickards is known for correctly predicting the biggest market shocks of the last 20 years.tc pixel
Intensity (INTS) Q3 2026 Earnings Call Transcript
See More Intensity Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Intensity Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Intensity Therapeutics and other key companies, straight to your email.

About Intensity Therapeutics

Intensity Therapeutics (NASDAQ:INTS), Inc. is a clinical-stage biotechnology company developing treatments for solid tumors. Its approach centers on delivering cancer-killing agents directly into tumors, with the goal of treating the tumor while also stimulating an immune response.

The company’s lead investigational product, INT230-6, combines the chemotherapy agents cisplatin and vinblastine sulfate with a proprietary molecule intended to help the drugs spread through tumor tissue and enter cancer cells. Intensity has evaluated INT230-6 in clinical studies as a treatment for solid tumors.

Founded in 2012, Intensity Therapeutics is led by founder and Chief Executive Officer Lewis Barger. Its work is focused on developing and clinically testing its intratumoral treatment platform.

View Intensity Therapeutics Profile